Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC). We conducted a single arm phase II study to evaluate the safety and efficacy of bevacizumab in combination with dose-reduced capecitabine and irinotecan in patients with previously untreated mCRC.

Patients and methods

Patients with previously untreated mCRC were eligible. Capecitabine was given at 1,000 mg/m2 orally twice daily for 14 days and dose was reduced to 750 mg/m2 for patients over 65. Irinotecan was given at 200 mg/m2 and bevacizumab was given at 7.5 mg/kg intravenously on day 1. The treatment cycle was repeated every 21 days. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival, response rate, and toxicity.

Results

Fifty patients were enrolled, the median age was 58, and 54% were ECOG 0. The most common grade 3/4 adverse events included hand-foot syndrome (14%), neutropenia (12%), and diarrhea (10%). Response rate was 51% and disease control rate (response and stable disease) was 98%. Median PFS was 11.5 months (95% CI: 9.2–13.7), and 6 month PFS was 90% (95% CI: 77–98%).

Conclusion

With modest dose reductions, the combination of capecitabine, irinotecan, and bevacizumab was well tolerated and resulted in favorable outcomes for patients with previously untreated mCRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96

    Article  PubMed  Google Scholar 

  2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581–592

    Article  PubMed  CAS  Google Scholar 

  3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342

    Article  PubMed  CAS  Google Scholar 

  4. Giantonio BJ, Levy DE, O’dwyer PJ, Meropol NJ, Catalano PJ, Benson AB III et al (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17(9):1399–1403

    Article  PubMed  CAS  Google Scholar 

  5. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544

    Article  PubMed  CAS  Google Scholar 

  6. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019

    Article  PubMed  CAS  Google Scholar 

  7. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326–5334

    Article  PubMed  CAS  Google Scholar 

  8. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847

    Article  PubMed  CAS  Google Scholar 

  9. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 23(22):4866–4875

    Article  PubMed  CAS  Google Scholar 

  10. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947

    PubMed  Google Scholar 

  11. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047

    Article  PubMed  CAS  Google Scholar 

  12. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147

    PubMed  CAS  Google Scholar 

  13. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23(22):4856–4865

    Article  PubMed  Google Scholar 

  14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905–914

    Article  PubMed  CAS  Google Scholar 

  15. Sorbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M et al (2004) Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 22(1):31–38

    Article  PubMed  CAS  Google Scholar 

  16. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040–2048

    Article  PubMed  CAS  Google Scholar 

  17. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658–1664

    Article  PubMed  Google Scholar 

  18. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13(4):566–575

    Article  PubMed  CAS  Google Scholar 

  19. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C et al (2001) Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37(5):597–604

    Article  PubMed  CAS  Google Scholar 

  20. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106

    PubMed  Google Scholar 

  21. Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR (2004) Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 26(4):579–589

    Article  PubMed  Google Scholar 

  22. Czejka M, Schueller J, Hauer K, Ostermann E (2005) Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer. Anticancer Res 25(4):2985–2990

    PubMed  CAS  Google Scholar 

  23. Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T et al (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16(7):1123–1132

    Google Scholar 

  24. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S et al (2004) Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100(2):279–287

    Article  PubMed  CAS  Google Scholar 

  25. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P et al (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16(2):282–288

    Article  PubMed  CAS  Google Scholar 

  26. Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L (2005) Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5(1):50–56

    Article  PubMed  CAS  Google Scholar 

  27. Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS et al (2005) Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta Oncol 44(3):230–235

    Article  PubMed  CAS  Google Scholar 

  28. Park SH, Bang SM, Cho EK, Baek JH, Oh JH, Im SA et al (2004) First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 66(5):353–357

    Article  PubMed  CAS  Google Scholar 

  29. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25(30):4779–4786

    Article  PubMed  CAS  Google Scholar 

  30. Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K et al (2008) Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19(5):920–926

    Article  PubMed  Google Scholar 

  31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  32. Garcia-Alfonso P, Munoz-Martin AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P et al (2010) Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer 103(10):1524–1528

    Article  PubMed  CAS  Google Scholar 

  33. Ducreux M, Adenis A, Mendiboure E et al (2009) Efficacy and safety of bevacizumab (BEV)—based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV+FOLFIRI versus BEV+XELIRI (FNCLCC ACCORD 13/0503 study). J Clin Oncol 27:15s

    Google Scholar 

  34. Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2):113–119

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Partially funding for this study was provided by Hoffmann-La-Roche Canada.

Conflicts of interest

D. Renouf received honoraria from Roche; S. Welch received honoraria and travel grants from Roche; R. Feld received research funding from Roche; M. Krzyzanowska received honoraria from Sanofi Aventis; E. Chen received research funding from Roche.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, University Health Network-Princess Margaret Hospital, Rm 5-719, 610 University Avenue, Toronto, ON, M5G2M9, Canada

    Malcolm J. Moore, Monika K. Krzyzanowska, Jennifer Knox, Ronald Feld, Geoffrey Liu, Helen MacKay, Jennifer Petronis & Eric Chen

  2. Department of Medical Oncology, London Regional Cancer Centre, Toronto, ON, Canada

    Stephen Welch

  3. Department of Biostatistics, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

    Lisa Wang

  4. Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

    Daniel J. Renouf

Authors
  1. Daniel J. Renouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Welch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malcolm J. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monika K. Krzyzanowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer Knox
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ronald Feld
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Geoffrey Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Helen MacKay
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jennifer Petronis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lisa Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eric Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Renouf, D.J., Welch, S., Moore, M.J. et al. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol 69, 1339–1344 (2012). https://doi.org/10.1007/s00280-012-1843-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1843-9

Keywords

Search

Navigation